{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:29:01Z","timestamp":1790810941744,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The surveillance of drug resistance among tuberculosis (TB) patients is central to preventing the spread of antimicrobial resistance. The Democratic Republic of the Congo (DR Congo) is classified by the World Health Organization (WHO) as a country with a high burden of\u00a0TB and multidrug-resistant TB (MDR-TB), but there are no nationally representative data on drug\u00a0resistance. In 2016\u20132017, a national survey of TB patients was conducted in 108 microscopy centres across all 11 provinces of the country using innovative molecular approaches. Sputum samples were collected from 1,545 new and 163 previously treated patients. These were tested by the Xpert MTB\/RIF assay, followed by targeted next-generation sequencing performed directly on sputum. The prevalence of rifampicin resistance was low, at 1.8% (95% CI: 1.0\u20133.2) among new and 17.3% (95% CI: 11.9\u201324.4) among previously treated patients. Resistance to pyrazinamide, fluoroquinolones and second-line injectables was also low. The prevalence of resistance to isoniazid among rifampicin-susceptible patients was higher, at 6.6% (95% CI: 4.4\u20139.8) among new and 8.7% (95% : 3.2\u201321.2) among previously treated patients. Diagnosing and treating isoniazid-resistant patients remains a challenge, given that many will be missed by the current national diagnostic algorithm that is driven by detecting rifampicin resistance by Xpert MTB\/RIF. This is the first nationwide survey incorporating targeted sequencing directly on sputum. It serves as a proof-of-concept for other settings that do yet have rapid specimen transport networks or capacity to conduct culture.<\/jats:p>","DOI":"10.1038\/s41598-020-67479-4","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T10:40:20Z","timestamp":1593600020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Targeted next-generation sequencing of sputum for diagnosis of\u00a0drug-resistant TB: results of a national survey in Democratic\u00a0Republic of the\u00a0Congo"],"prefix":"10.1038","volume":"10","author":[{"given":"Michel Kaswa","family":"Kayomo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vital Nkake","family":"Mbula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Aloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Rigouts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fairouz","family":"Boutachkourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouke C.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas M.","family":"Nkiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"67479_CR1","unstructured":"World Health Organization. Guidelines for Surveillance of Drug Resistance in Tuberculosis 5th edn. (2015)."},{"key":"67479_CR2","unstructured":"World Health Organization. Global Tuberculosis Report. (2019)."},{"key":"67479_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2334-14-2","volume":"14","author":"J Creswell","year":"2014","unstructured":"Creswell, J. et al. Results from early programmatic implementation of Xpert MTB\/RIF testing in nine countries. BMC Infect. Dis. 14, 2 (2014).","journal-title":"BMC Infect. Dis."},{"key":"67479_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1556\/1886.2018.00001","volume":"8","author":"K N\u2019Guessan","year":"2018","unstructured":"N\u2019Guessan, K. et al. Multidrug-resistant tuberculosis in C\u00f4te d\u2019Ivoire from 1995 to 2016: Results of national surveys. Eur. J. Microbiol. Immunol. 8, 91\u201394 (2018).","journal-title":"Eur. J. Microbiol. Immunol."},{"key":"67479_CR5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/tmi.13205","volume":"24","author":"V Iem","year":"2019","unstructured":"Iem, V. et al. Low prevalence of MDR-TB in Lao PDR: Results from the first national anti-tuberculosis drug resistance survey. Trop. Med. Int. Health TM IH 24, 421\u2013431 (2019).","journal-title":"Trop. Med. Int. Health TM IH"},{"key":"67479_CR6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.5588\/ijtld.15.0645","volume":"20","author":"S Tahseen","year":"2016","unstructured":"Tahseen, S. et al. Use of Xpert(\u00ae) MTB\/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan. Int. J. Tuberc. Lung Dis. 20, 448\u2013455 (2016).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"67479_CR7","doi-asserted-by":"crossref","unstructured":"World Health Organization. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. (2019).","DOI":"10.4103\/ijmr.IJMR_579_19"},{"key":"67479_CR8","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S1473-3099(16)30190-6","volume":"16","author":"M Zignol","year":"2016","unstructured":"Zignol, M. et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: Results from a multicountry surveillance project. Lancet Infect. Dis. 16, 1185\u20131192 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"67479_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30073-2","author":"M Zignol","year":"2018","unstructured":"Zignol, M. et al. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: A multi-country population-based surveillance study. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(18)30073-2 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"67479_CR10","unstructured":"Andre, E., Chirambiza, J., Nyota, R. & Kalumuna, D. Alcohol-based conservation of sputum\u202f: quantitative and qualitative impact among referred samples from distant centers for GeneXpert MTB\/Rif analysis. Int. J. Tuberc. Lung Dis. s106\u2013s107 (2012)."},{"key":"67479_CR11","unstructured":"Promega. Maxwell\u00ae 16 DNA Purification Kits Protocol. (2017)."},{"key":"67479_CR12","unstructured":"Deeplex Myc-TB. https:\/\/www.genoscreen.fr\/en\/genoscreen-services\/products\/deeplex."},{"key":"67479_CR13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S1473-3099(15)00062-6","volume":"15","author":"TM Walker","year":"2015","unstructured":"Walker, T. M. et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: A retrospective cohort study. Lancet Infect. Dis. 15, 1193\u20131202 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"67479_CR14","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1128\/JCM.00025-15","volume":"53","author":"S Feuerriegel","year":"2015","unstructured":"Feuerriegel, S. et al. PhyResSE: A web tool delineating Mycobacterium tuberculosis antibiotic resistance and lineage from whole-genome sequencing data. J. Clin. Microbiol. 53, 1908\u20131914 (2015).","journal-title":"J. Clin. Microbiol."},{"key":"67479_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-33731-1","volume":"8","author":"M Ezewudo","year":"2018","unstructured":"Ezewudo, M. et al. Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase. Sci. Rep. 8, 1\u201310 (2018).","journal-title":"Sci. Rep."},{"key":"67479_CR16","doi-asserted-by":"crossref","unstructured":"Miotto, P. et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur. Respir. J. 50 (2017).","DOI":"10.1183\/13993003.01354-2017"},{"issue":"Suppl 3","key":"67479_CR17","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1093\/cid\/civ610","volume":"61","author":"AM Starks","year":"2015","unstructured":"Starks, A. M. et al. Collaborative effort for a centralized worldwide tuberculosis relational sequencing data platform. Clin. Infect. Dis. 61(Suppl 3), S141-146 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"67479_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1128\/JCM.01489-06","volume":"45","author":"L Rigouts","year":"2007","unstructured":"Rigouts, L. et al. Newly developed primers for comprehensive amplification of the rpoB gene and detection of rifampin resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 45, 252\u2013254 (2007).","journal-title":"J. Clin. Microbiol."},{"key":"67479_CR19","doi-asserted-by":"publisher","first-page":"eaat5869","DOI":"10.1126\/sciadv.aat5869","volume":"4","author":"OB Brynildsrud","year":"2018","unstructured":"Brynildsrud, O. B. et al. Global expansion of Mycobacterium tuberculosis lineage 4 shaped by colonial migration and local adaptation. Sci. Adv. 4, eaat5869 (2018).","journal-title":"Sci. Adv."},{"key":"67479_CR20","unstructured":"Evaluation of the analytical performance of the Xpert MTB\/RIF assay. PubMed-NCBI. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20504986."},{"key":"67479_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1473-3099(16)30407-8","volume":"17","author":"M Gegia","year":"2017","unstructured":"Gegia, M., Winters, N., Benedetti, A., van Soolingen, D. & Menzies, D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: A systematic review and meta-analysis. Lancet Infect. Dis. 17, 223\u2013234 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"67479_CR22","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1038\/s41598-018-21378-x","volume":"8","author":"P Lempens","year":"2018","unstructured":"Lempens, P. et al. Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. Sci. Rep. 8, 3246 (2018).","journal-title":"Sci. Rep."},{"key":"67479_CR23","doi-asserted-by":"crossref","unstructured":"Ghodousi, A. et al. Isoniazid resistance in Mycobacterium tuberculosis is a heterogeneous phenotype comprised of overlapping MIC distributions with different underlying resistance mechanisms. Antimicrob. Agents Chemother. 63 (2019).","DOI":"10.1128\/AAC.00092-19"},{"key":"67479_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.5588\/ijtld.16.0619","volume":"21","author":"HL Rieder","year":"2017","unstructured":"Rieder, H. L. & Van Deun, A. Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 21, 123\u2013124 (2017).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"67479_CR25","first-page":"S231","volume":"3","author":"W Fox","year":"1999","unstructured":"Fox, W., Ellard, G. A. & Mitchison, D. A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946\u20131986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis. 3, S231-279 (1999).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"67479_CR26","doi-asserted-by":"publisher","first-page":"17672","DOI":"10.1038\/s41598-017-17705-3","volume":"7","author":"E Tagliani","year":"2017","unstructured":"Tagliani, E. et al. Culture and next-generation sequencing-based drug susceptibility testing unveil high levels of drug-resistant-TB in Djibouti: Results from the first national survey. Sci. Rep. 7, 17672 (2017).","journal-title":"Sci. Rep."},{"key":"67479_CR27","unstructured":"World Health Organization. Xpert MTB\/RIF Implementation Manual. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/112469\/9789241506700_eng.pdf;jsessionid=21352236EA537B86079ED0D6C9773F3A?sequence=1 (2014)."},{"key":"67479_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.diagmicrobio.2016.01.009","volume":"85","author":"O Ocheretina","year":"2016","unstructured":"Ocheretina, O. et al. False-positive Rifampin resistant results with Xpert MTB\/RIF version 4 assay in clinical samples with a low bacterial load. Diagn. Microbiol. Infect. Dis. 85, 53\u201355 (2016).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"67479_CR29","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.5588\/ijtld.17.0792","volume":"22","author":"M Sahrin","year":"2018","unstructured":"Sahrin, M. et al. Discordance in Xpert\u00ae MTB\/RIF assay results among low bacterial load clinical specimens in Bangladesh. Int. J. Tuberc. Lung Dis. 22, 1056\u20131062 (2018).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"67479_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1465-9921-7-99","volume":"7","author":"IC Shamputa","year":"2006","unstructured":"Shamputa, I. C. et al. Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. Respir. Res. 7, 99 (2006).","journal-title":"Respir. Res."},{"key":"67479_CR31","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1128\/JCM.02489-13","volume":"52","author":"NM Zetola","year":"2014","unstructured":"Zetola, N. M. et al. Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB\/RIF are associated with poor clinical outcomes. J. Clin. Microbiol. 52, 2422\u20132429 (2014).","journal-title":"J. Clin. Microbiol."},{"key":"67479_CR32","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1128\/JCM.00128-10","volume":"48","author":"R Blakemore","year":"2010","unstructured":"Blakemore, R. et al. Evaluation of the analytical performance of the Xpert MTB\/RIF assay. J. Clin. Microbiol. 48, 2495\u20132501 (2010).","journal-title":"J. Clin. Microbiol."},{"key":"67479_CR33","doi-asserted-by":"publisher","first-page":"864","DOI":"10.5588\/ijtld.15.0977","volume":"20","author":"AS Dean","year":"2016","unstructured":"Dean, A. S. et al. Sputum smear microscopy result: A predictor for drug-resistant tuberculosis?. Int. J. Tuberc. Lung Dis. 20, 864\u2013865 (2016).","journal-title":"Int. J. Tuberc. Lung Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67479-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67479-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67479-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T13:11:24Z","timestamp":1670332284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67479-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["67479"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-67479-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]},"assertion":[{"value":"5 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10786"}}